Live Cell Encapsulation technology is a methodology allowing implantation of xenogeneic cells while isolating the cells from host immune response allowing blood to enter and nourish the living cells inside them. The encapsulation technology was first incorporated around 9 decades ago in a report of 1934 that described the encapsulation of tumor cells in a polymer as well as implanting the capsules in the abdominal cavity of a pig.
Cell encapsulation is probably the solution for most of the chronic disease, which had not yet been attended by most of the pharmaceutical therapeutics. The cellular system might possibly enable seamless treatment in upcoming years as certain clinical trials are evaluating the use of encapsulated cells for several human diseases.
Cell encapsulation includes immobilization of xenogeneic cells within a semipermeable, yet in immunoprotective membrane. Thus, it offers therapeutics’ without requiring immunosuppression. Potentials of the therapeutics have been taken from two key instances; islet cell delivery for diabetes and MSCs-based therapies.
“I think diabetes is where this type of technology really lends itself to the application. The key is to develop the right type of cell line to treat Type 1 and insulin-dependent Type 2 diabetes. There are several cell lines being explored by PharmaCyte simultaneously to do this,” said David A. Judd, a cellular biologist and a member of PharmaCyte’s Medical and Scientific Advisory Board in a press release. PharmaCyte Biotech, a global biotechnology company that has been in the market for a while now and is already developing therapies for both diabetes and cancer using cell-based cell encapsulation technology (Cell-in-a-Box®).
The technology further is the representation of a process with an ample amount of applications. These when combined together offers an ability of preserving cells within the encapsulation matrix. The applications include:
The global market for live cell encapsulation has a highly competitive landscape with large number of players developing cell-based therapies. Despite the market having a huge scope, there are certain limitations impeding it growth, like lack of technical skills, limited availability of high quality raw material and the significant adoption of alternative therapies as per the report by The Insight partners.
The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials.
Severity: Warning
Message: count(): Parameter must be an array or an object that implements Countable
Filename: amp/news_details_amp.php
Line Number: 252
Backtrace:
File: /home/smartmarketnews/public_html/application/views/amp/news_details_amp.php
Line: 252
Function: _error_handler
File: /home/smartmarketnews/public_html/application/controllers/Amp_controller.php
Line: 41
Function: view
File: /home/smartmarketnews/public_html/index.php
Line: 315
Function: require_once
Smarter Decisions with Smart News
Smart Market News is committed to getting its readers the latest updates and insights on industries that help in making “smarter” business decisions. With insights and inputs from corporate decision makers, we bring you the stories of adopting innovative solutions and strategies that have been changing the world. Our editorial insights on products, solutions, companies, and adoption of best practices not only help in understanding the markets better, but also prove to be a complete package for your information needs.
media@smartmarketnews.com | sales@smartmarketnews.com
Contact Us